More trials. Less tribulations.
Our mission is to move fast to fund clinical trials and support frontline researchers — catalyzing annual improvement to end ovarian cancer while providing patients and doctors with the information they need. Because action saves lives.
Why usOver $1.9 million raised so far.
Learn about the studies and trials we’ve helped fund. More are being added every week. Because nobody has time to wait 5+ years between raising the funds and doing the actual research.
Funded $ 1,800,000
Novel Research in Borderline and Low-Grade Serous Ovarian Cancer
Treatment options for patients with borderline ovarian tumors and low-grade serous ovarian cancer are very limited, and progression can be difficult to predict and then treat.
Because these types are rare, there is a lack of scientific data and research to provide surveillance guidelines needed to monitor the progression of borderline ovarian tumors into serous ovarian cancers, predict if and how recurrence will occur, and understand the underlying genetic changes between borderline and low-grade serous ovarian cancers which could inform treatment.
To address this need, investigators in the Division of Gynecology Oncology, led by Ursula Matulonis, MD, launched an innovative research project for borderline ovarian tumors and low-grade serous ovarian cancer. The project aimed to enhance the field’s understanding of the spectrum of these diseases, introduce improved surveillance strategies to identify at-risk patients earlier, and expand treatment options and improve the quality of life for patients.
This project was generously funded by NTO board members, Patricia Farah’s estate, and various other private supporters prior to the formal incorporation of NTO. This project become the catalyst for the board members and others involved to start the charity Not These Ovaries and to fund this important research.
Funded $100,000
Gynecologic Oncology Research Supervisor
The goal of this research supervisor is to establish a formalized program of investigating any low-grade series of cancer (LGSOC) and borderline tumors (BOT), as well as to oversee and track active clinical trials and new affiliations for our patients’ participation. The research supervisor reports directly to Dr. Slomovitz at Mount Sinai Medical Center, based in Miami Beach, Florida.
This funding launches research initiatives and tracks the outcomes to gain a better understanding of this disease. We believe in amplifying Dr. Slomovitz's impact with additional staff for research and more patient trials to improve the outcome for LGSOC and BOT patients. This project has been funded for one year starting in the spring of 2024.